Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Roche and Trimeris amend HIV fusion inhibitors agreement

Roche and Trimeris amend HIV fusion inhibitors agreement

19th March 2007

Trimeris has announced that it has amended its research agreement signed with Roche in 2002 relating to next-generation HIV fusion inhibitor peptides. Under the terms of the amended partnership agreement, Trimeris will be granted all intellectual property and joint patents relating to the compounds in exchange for a nominal royalty on the future sales of TRI-1144, up to a set limit.

Furthermore, Roche will also return the rights granted under the firms’ development and license agreement signed in 1999, with the exception to the global licensing and manufacturing rights to Fuzeon, with the commercial partnership between the companies on this compound remaining as they were.

“Roche retains the right to conduct research on certain HIV gp41 fusion inhibitor peptides at Roche’s costs for a specified period of time,” the company reports.

It added that Trimeris keeps the right to co-develop one of these compounds with both cost and profit split evenly worldwide.

Analyst Edward Nash from Stifel, Nicolaus & Co commented that this move indicates that Roche contends injectible HIV fusion inhibitor peptides will not be popular in the future, with patients preferring the oral administration of oral medication, Reuters reports.

He added that the investment firm backed this judgement, believing that Fuzeon may be replaced by orally-administered compounds from competitors such as Pfizer in the future.

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.